Topical Botulinum Toxin Ocular Delivery via Lipid Membrane Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular allergy, ocular surface disease, and inflammation require frequent dosing of topical anesthetics and anti-inflammatory medications, which are inconvenient and lead to compliance issues, whereas botulinum toxin injections around the eye are discomforting due to needle penetration.
Innovation Solution
A composition combining botulinum toxin with topical anesthetics, such as tetracaine, lidocaine, or bupivacaine, in a formulation that allows long-term duration of action by enhanced penetration through lipid membranes, particularly when applied before sleep to leverage diurnal osmotic changes in the eye, providing a painless and sustained treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If botulinum toxin is administered via periocular injection, then therapeutic effect is achieved, but patient comfort deteriorates due to needle penetration discomfort
Solution Approach 1:
The patent replaces the mechanical injection method (needle penetration) with a topical application method (eye drops). The botulinum toxin is delivered through ocular surface absorption rather than direct injection, substituting a painful mechanical intervention with a non-invasive topical application while maintaining therapeutic efficacy.
Solution Approach 2:
The patent uses the ocular surface (tear film and corneal epithelium) as an intermediary medium to deliver botulinum toxin to the periocular region. Instead of direct needle injection, the toxin is applied topically and transported through physiological pathways (tear drainage, lymphatic flow) to reach the target area, using the body's own structures as delivery vehicles.
2Reliability
If frequent dosing of topical anesthetics and anti-inflammatory medications is used, then treatment coverage is improved, but patient compliance deteriorates due to inconvenience
Solution Approach 1:
The patent changes the dosing frequency parameter from frequent administration (multiple times daily) to less frequent administration (once or twice weekly). This parameter change in dosing schedule maintains therapeutic coverage while significantly improving patient compliance by reducing the burden of frequent dosing.
Solution Approach 2:
The patent achieves continuous therapeutic effect through a single topical application that provides sustained release of botulinum toxin. The long-acting nature of the toxin, combined with its accumulation in the periocular region through physiological pathways, maintains continuous therapeutic action without requiring frequent re-dosing, thereby improving compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach offers a long-acting, painless treatment option for ocular surface inflammation and allergy, reducing the need for frequent dosing and enhancing penetration, thereby improving patient compliance and treatment efficacy without the side effects of corticosteroids.
Implementation Method 1
leverage diurnal osmotic changes in the eye
Data Source
AI summary
A composition of botulinum toxin is claimed which can penetrate into the ocular surface inclusive of a penetration through a conjunctiva, cornea, and other structures. This composition allows for a maximal penetration of a topical preparation of botulinum toxin which serves to reduce the need for frequent allergy drops for the treatment of ocular surface disease and other conditions causing ocular surface inflammation or deep ocular inflammation. No puncture of the needle is necessary for the administration. Herein describes a novel composition using several principles based on composition, method of application, which enhances the effectiveness of the penetration.